Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033971288> ?p ?o ?g. }
- W2033971288 endingPage "1155" @default.
- W2033971288 startingPage "1148" @default.
- W2033971288 abstract "Within the concept of reduced-intensity stem cell transplantation (RIST) there is a wide range of different regimens used, and little information is available on the clinical impact of chimerism status in patients conditioned with a busulfan-containing regimen. Therefore, we retrospectively reviewed lineage-specific chimerism and the subsequent clinical outcome in 117 patients (median age, 55 years; range: 29-68) who underwent busulfan-containing RIST. The conditioning regimen consisted of busulfan (oral 8 mg/kg or i.v. 6.4 mg/kg) and fludarabine (180 mg/m2, n = 64) or cladribine (0.66 mg/kg, n = 53), with or without 2-4 Gy total-body irridiation (TBI) (n = 26) or antihuman T-lymphocyte immunoglobulin (ATG; 5-10 mg/kg; n = 31). Chimerism was evaluated with peripheral blood samples taken on days 30, 60, and 90 after transplantation by polymerase chain reaction (PCR)-based amplification of polymorphic short tandem repeat regions. The median follow-up of surviving patients was 1039 days (153-2535). The percent donor-chimerism was significantly higher in granulocyte than T cell fraction throughout the entire course, and the median (mean) values were, respectively, 100% (96%) versus 95% (83%), 100% (98%) versus 100% (89%), and 100% (98%) versus 100% (91%) at days 30, 60, and 90 after RIST. In a multivariate analysis, having received <2 types of chemotherapy regimens before RIST was the only factor that was significantly associated with low donor T cell chimerism (<60%) at day 30 (hazard ratio [HR]: 6.1; 95% confidence interval [CI], 2.1-18.4; P < .01). The median percentage of donor T cell chimerism at day 30 was 9% (0%-63%) in 5 patients who experienced graft failure, which was significantly lower than that (97%; 15%-100%) in the rest of the patients (P < .01). No correlation was found between the kinetics of T cell chimerism and the occurrence of acute or chronic GVHD (aGVHD, cGVHD). The stem cell source and the addition of TBI or ATG were not associated with the degree of T cell chimerism, overall survival (OS) or event-free survival (EFS). In a Cox proportional hazard model, low donor T cell chimerism of <60% at day 30 was associated with both poor OS (HR: 2.2; 95% CI, 1.1-4.5; P = .02) and EFS (HR: 2.0; 95% CI, 1.1-3.8; P = .02). In conclusion, we found that 43% of the patients retained mixed donor T cell chimerism (<90% donor) at day 30, whereas 92% achieved complete chimerism in granulocyte fraction. Low donor T cell chimerism of <60% at day 30 may predict a poor outcome, and a prospective study to examine the value of early intervention based on chimerism data is warranted." @default.
- W2033971288 created "2016-06-24" @default.
- W2033971288 creator A5001196940 @default.
- W2033971288 creator A5005153787 @default.
- W2033971288 creator A5012306452 @default.
- W2033971288 creator A5025709914 @default.
- W2033971288 creator A5035038653 @default.
- W2033971288 creator A5041862198 @default.
- W2033971288 creator A5046575430 @default.
- W2033971288 creator A5051620715 @default.
- W2033971288 creator A5058291323 @default.
- W2033971288 creator A5065025175 @default.
- W2033971288 creator A5075059650 @default.
- W2033971288 creator A5080050866 @default.
- W2033971288 creator A5087293390 @default.
- W2033971288 date "2008-10-01" @default.
- W2033971288 modified "2023-10-16" @default.
- W2033971288 title "Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen" @default.
- W2033971288 cites W1547120987 @default.
- W2033971288 cites W1864748840 @default.
- W2033971288 cites W1912693401 @default.
- W2033971288 cites W1964949071 @default.
- W2033971288 cites W1982912364 @default.
- W2033971288 cites W2004644657 @default.
- W2033971288 cites W2014751151 @default.
- W2033971288 cites W2016231795 @default.
- W2033971288 cites W2018246175 @default.
- W2033971288 cites W2020296640 @default.
- W2033971288 cites W2029173845 @default.
- W2033971288 cites W2031206337 @default.
- W2033971288 cites W2053278212 @default.
- W2033971288 cites W2055034746 @default.
- W2033971288 cites W2074588389 @default.
- W2033971288 cites W2082858272 @default.
- W2033971288 cites W2085074865 @default.
- W2033971288 cites W2086812421 @default.
- W2033971288 cites W2128185637 @default.
- W2033971288 cites W2131706663 @default.
- W2033971288 cites W2138338051 @default.
- W2033971288 cites W2159507916 @default.
- W2033971288 cites W2165628873 @default.
- W2033971288 cites W4246085869 @default.
- W2033971288 cites W4293241248 @default.
- W2033971288 cites W4376595466 @default.
- W2033971288 doi "https://doi.org/10.1016/j.bbmt.2008.07.013" @default.
- W2033971288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18804045" @default.
- W2033971288 hasPublicationYear "2008" @default.
- W2033971288 type Work @default.
- W2033971288 sameAs 2033971288 @default.
- W2033971288 citedByCount "39" @default.
- W2033971288 countsByYear W20339712882012 @default.
- W2033971288 countsByYear W20339712882013 @default.
- W2033971288 countsByYear W20339712882014 @default.
- W2033971288 countsByYear W20339712882015 @default.
- W2033971288 countsByYear W20339712882016 @default.
- W2033971288 countsByYear W20339712882017 @default.
- W2033971288 countsByYear W20339712882018 @default.
- W2033971288 countsByYear W20339712882019 @default.
- W2033971288 countsByYear W20339712882020 @default.
- W2033971288 countsByYear W20339712882022 @default.
- W2033971288 countsByYear W20339712882023 @default.
- W2033971288 crossrefType "journal-article" @default.
- W2033971288 hasAuthorship W2033971288A5001196940 @default.
- W2033971288 hasAuthorship W2033971288A5005153787 @default.
- W2033971288 hasAuthorship W2033971288A5012306452 @default.
- W2033971288 hasAuthorship W2033971288A5025709914 @default.
- W2033971288 hasAuthorship W2033971288A5035038653 @default.
- W2033971288 hasAuthorship W2033971288A5041862198 @default.
- W2033971288 hasAuthorship W2033971288A5046575430 @default.
- W2033971288 hasAuthorship W2033971288A5051620715 @default.
- W2033971288 hasAuthorship W2033971288A5058291323 @default.
- W2033971288 hasAuthorship W2033971288A5065025175 @default.
- W2033971288 hasAuthorship W2033971288A5075059650 @default.
- W2033971288 hasAuthorship W2033971288A5080050866 @default.
- W2033971288 hasAuthorship W2033971288A5087293390 @default.
- W2033971288 hasBestOaLocation W20339712881 @default.
- W2033971288 hasConcept C126322002 @default.
- W2033971288 hasConcept C141071460 @default.
- W2033971288 hasConcept C207103383 @default.
- W2033971288 hasConcept C2776694085 @default.
- W2033971288 hasConcept C2776755627 @default.
- W2033971288 hasConcept C2777408962 @default.
- W2033971288 hasConcept C2778880498 @default.
- W2033971288 hasConcept C2779263901 @default.
- W2033971288 hasConcept C2780611847 @default.
- W2033971288 hasConcept C2781413609 @default.
- W2033971288 hasConcept C2911091166 @default.
- W2033971288 hasConcept C44249647 @default.
- W2033971288 hasConcept C71924100 @default.
- W2033971288 hasConcept C90924648 @default.
- W2033971288 hasConceptScore W2033971288C126322002 @default.
- W2033971288 hasConceptScore W2033971288C141071460 @default.
- W2033971288 hasConceptScore W2033971288C207103383 @default.
- W2033971288 hasConceptScore W2033971288C2776694085 @default.
- W2033971288 hasConceptScore W2033971288C2776755627 @default.
- W2033971288 hasConceptScore W2033971288C2777408962 @default.
- W2033971288 hasConceptScore W2033971288C2778880498 @default.
- W2033971288 hasConceptScore W2033971288C2779263901 @default.